# Verastem, Inc. clinical trials: 27 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 27 trials with Verastem, Inc. as lead sponsor, 6 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Verastem, Inc.: 27 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/verastem-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 27
- Recruiting or not yet: 6
- Read on: November 19, 2026

## Trials

The 25 newest of 27, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| August 5, 2026 | NCT07747506 | Continued Access to Avutometinib in Combination With Defactinib in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) | Verastem, Inc. | Phase 2 | Not yet recruiting | Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer | 2 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07747506) |
| June 22, 2026 | NCT07659795 | A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer | Verastem, Inc. | Phase 2 | Recruiting | Colorectal Cancer | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07659795) |
| June 22, 2026 | NCT07659782 | A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer | Verastem, Inc. | Phase 2 | Recruiting | Non-Small Cell Lung Cancer | 105 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07659782) |
| June 12, 2026 | NCT07644559 | A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer | Verastem, Inc. | Phase 2 | Recruiting | Pancreatic Ductal Adenocarcinoma (PDAC), G12D Mutated KRAS | 185 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07644559) |
| June 13, 2025 | NCT07020221 | A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors | Verastem, Inc. | Phase 1/2 | Recruiting | Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, Adult, G12D Mutated KRAS | 616 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07020221) |
| November 12, 2024 | NCT06682572 | A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients | Verastem, Inc. | Phase 2 | Active not recruiting | Low Grade Serous Ovarian Cancer, Ovarian Cancer | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06682572) |
| October 10, 2023 | NCT06072781 | A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer | Verastem, Inc. | Phase 3 | Recruiting | Low Grade Serous Ovarian Cancer | 270 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06072781) |
| December 30, 2022 | NCT05669482 | Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer | Verastem, Inc. | Phase 1/2 | Active not recruiting | KRAS Activating Mutation, Metastatic Cancer, Pancreas Cancer, Neoplasms Pancreatic, Malignant Neoplasm of Pancreas | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05669482) |
| May 17, 2022 | NCT05375994 | Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients | Verastem, Inc. | Phase 1/2 | Completed | Non Small Cell Lung Cancer, KRAS Activating Mutation, Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Lung... | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05375994) |
| January 11, 2022 | NCT05187169 | Food Effect of VS-6766 in Healthy Adult Subjects | Verastem, Inc. | Phase 1 | Completed | Food Effect | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05187169) |
| October 12, 2021 | NCT05074810 | Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients | Verastem, Inc. | Phase 1/2 | Active not recruiting | Non Small Cell Lung Cancer, KRAS Activating Mutation | 153 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05074810) |
| November 12, 2020 | NCT04625270 | A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a... | Verastem, Inc. | Phase 2 | Active not recruiting | Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer | 225 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04625270) |
| November 6, 2020 | NCT04620330 | A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer | Verastem, Inc. | Phase 2 | Completed | Non Small Cell Lung Cancer, KRAS Activating Mutation | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04620330) |
| October 24, 2016 | NCT02943317 | Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With... | Verastem, Inc. | Phase 1 | Terminated | Epithelial Ovarian Cancer | 98 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02943317) |
| September 26, 2016 | NCT02913716 | A Phase I, Open-label Study of Absorption, Metabolism, and Excretion of Defactinib (VS-6063) in Healthy Male Subjects | Verastem, Inc. | Phase 1 | Completed | Healthy Subjects | 5 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02913716) |
| January 11, 2016 | NCT02651727 | Ph 1 Study of VS-4718, a FAK Inhibitor, in Combination With Nab-paclitaxel and Gemcitabine in Advanced Cancer Subjects | Verastem, Inc. | Phase 1 | Terminated | Pancreatic Cancer | 13 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02651727) |
| February 26, 2015 | NCT02372227 | A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma | Verastem, Inc. | Phase 1 | Terminated | Relapsed Malignant Mesothelioma | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02372227) |
| August 13, 2014 | NCT02215629 | Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic Leukemia | Verastem, Inc. | Phase 1 | Withdrawn | Relapsed or Refractory Acute Myeloid Leukemia, Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02215629) |
| December 6, 2013 | NCT02004028 | Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma Participants | Verastem, Inc. | Phase 2 | Terminated | Malignant Pleural Mesothelioma | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02004028) |
| November 25, 2013 | NCT01991938 | Phase I Dose Escalation Study of VS-5584 in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma | Verastem, Inc. | Phase 1 | Terminated | Non Hematologic Cancers, Metastatic Cancer, Lymphoma | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01991938) |
| September 27, 2013 | NCT01951690 | Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer | Verastem, Inc. | Phase 2 | Completed | Non Small Cell Lung Cancer, Lung Cancer | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01951690) |
| September 16, 2013 | NCT01943292 | Phase I Dose Escalation Study of VS-6063 in Japanese Subjects With Non-Hematologic Malignancies | Verastem, Inc. | Phase 1 | Completed | Non Hematologic Cancers | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01943292) |
| June 6, 2013 | NCT01870609 | Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma | Verastem, Inc. | Phase 2 | Terminated | Malignant Pleural Mesothelioma | 344 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01870609) |
| May 8, 2013 | NCT01849744 | Phase I Dose Escalation Study of VS-4718 in Subjects With Metastatic Non-Hematologic Malignancies | Verastem, Inc. | Phase 1 | Terminated | Non Hematologic Cancers, Metastatic Cancer | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01849744) |
| January 29, 2013 | NCT01778803 | Phase I/Ib Study of Paclitaxel in Combination With VS-6063 in Patients With Advanced Ovarian Cancer | Verastem, Inc. | Phase 1 | Completed | Ovarian Cancer | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01778803) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 12 |
| Phase 1/2 | 4 |
| Phase 2 | 10 |
| Phase 3 | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 9 |
| Terminated | 7 |
| Recruiting | 5 |
| Active not recruiting | 4 |
| Not yet recruiting | 1 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Carcinoma, Non-Small-Cell Lung | 6 |
| Pancreatic Neoplasms | 5 |
| Neoplasm Metastasis | 5 |
| Ovarian Neoplasms | 4 |
| Lung Neoplasms | 3 |
| Mesothelioma, Malignant | 3 |
| Neoplasms | 2 |
| Colorectal Neoplasms | 2 |
| Carcinoma, Ovarian Epithelial | 1 |
| Head and Neck Neoplasms | 1 |
| Prostatic Neoplasms | 1 |
| Gastrointestinal Neoplasms | 1 |
| Biliary Tract Neoplasms | 1 |
| Cholangiocarcinoma | 1 |
| Appendiceal Neoplasms | 1 |
| Endometrial Neoplasms | 1 |
| Lymphoma | 1 |
| Recurrence | 1 |
| Leukemia, Myeloid, Acute | 1 |
| Burkitt Lymphoma | 1 |
| Leukemia | 1 |
| Mesothelioma | 1 |
| Adenoma | 1 |
| Neoplasms, Mesothelial | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Steakhouses in the United States](https://specstream.ai/data/businesses/steakhouses/united-states)
- [Cocktail bars in the United States](https://specstream.ai/data/businesses/cocktail-bars/united-states)
- [Lumber stores in the United States](https://specstream.ai/data/businesses/lumber-stores/united-states)
- [Truck repair shops in the United States](https://specstream.ai/data/businesses/truck-repair-shops/united-states)
- [Distribution companies in the United States](https://specstream.ai/data/businesses/distribution-companies/united-states)
- [Nigerian restaurants in the United States](https://specstream.ai/data/businesses/nigerian-restaurants/united-states)
